thermotherapy is a potential treatment for CNV. It is able to close choroidal neovascularisation while maintaining visual function in patients with classic and occult disease. Further trials of TTT are needed to compare this intervention with the natural history and other treatment modalities. (Br J Ophthalmol 2001;85:173-178) Age related macular degeneration (ARMD) is the leading cause of visual loss in the developed world and choroidal neovascularisation (CNV) is the main cause of severe visual loss in this group.
Age related macular degeneration (ARMD) is the leading cause of visual loss in the developed world and choroidal neovascularisation (CNV) is the main cause of severe visual loss in this group. [1] [2] [3] [4] Laser photocoagulation treatment for classic CNV reduces the incidence of severe visual loss in patients with extrafoveal and juxtafoveal membranes. However, because photocoagulation damages neurosensory mechanisms, severe visual loss is often experienced in patients with subfoveal lesions. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The benefits of laser treatment are also reduced by recurrence in many patients. 9 In addition, 85-90% of patients with CNV are not eligible for argon laser treatment because the CNV is occult, or subfoveal and large. [1] [2] [3] The limitations of photocoagulation have led to a proliferation of new treatments (photodynamic therapy, [11] [12] [13] [14] radiotherapy, 15 interferon 2, 16 macular rotation, 17 18 and submacular membrane excision for occult and subfoveal lesions 19 ). The diode laser (emission wavelength 810 nm, near infrared) has a number of biophysical advantages in the treatment of macular disease. It has low absorption in xanthophyll, minimising nerve fibre layer damage, it is poorly absorbed by haemoglobin, allowing treatment through preretinal and subretinal blood but is mainly absorbed in the choroid, enabling eVective treatment of choroidal lesions. 20 Initial studies using photocoagulation have shown it to be eVective in closing CNV 21 22 and in treating macular oedema. 23 24 Low irradiance, long pulse diode laser irradiation ("transpupillary thermotherapy; TTT") has been usefully employed for the treatment of choroidal melanomas. 25 26 A recent report by Reichel and colleagues 27 has further demonstrated the benefit of diode laser TTT for the treatment of subfoveal CNV. In a non-randomised case selected pilot study, 94% of CNV showed clinical or angiographic improvement and vision was stabilised or improved in 75%. Optical coherence tomography demonstrated membrane resolution with a restoration of the retinal anatomy.
We aimed to assess the eYcacy of transpupillary thermotherapy for the treatment of both classic and occult CNV.
Materials and methods
Forty two consecutive patients with CNV secondary to ARMD, referred to the retinal clinic at King's College Hospital, were recruited to a non-randomised pilot trial. Baseline characteristics and eligibility criteria are shown in Table  1 . The patients were over 55, had signs of ARMD, and had symptoms of visual loss or metamorphopsia within the previous 4 months. There was angiographic evidence of CNV with or without pigment epithelial detachment. The Snellen visual acuity ranged between 6/9 and counting fingers. Patients who had received previous photocoagulation or were on alternative treatments for AMD were excluded from the trial, as were patients with other serious ocular disease or medical conditions that would prevent them from completing treatment.
BASELINE EXAMINATION
Initial clinical assessment included Snellen visual acuity, anterior segment examination, IOP measurement, mydriasis with 1% tropica-mide, and funduscopy with a 78D or 60D Volk lens (Volk Optical, Mentor, OH, USA). Following this, patients were assessed with digital or photographic fundus colour (Topcon, Tokyo, Japan) and fluorescein angiography (sodium fluorescein 5 ml, 10%). Patients were counselled as to the prognosis for their condition and their treatment options. Patients not willing to undergo treatment or to complete the counselling were excluded from the trial. The patients consented to treatment and the investigation took place with the recognition of the King's College Hospital ethics committee.
TREATMENT PROTOCOL Treatment was scheduled between 1 hour and 4 days of the initial angiogram. The membranes were classified in accordance with their angiographic appearance. Transpupillary thermotherapy with an 810 nm diode laser (Iris Medical OcuLight SLx, Iridex Corporation, Mountain View, CA, USA), was delivered through a dedicated slit lamp mounted delivery system. Laser settings were adjusted to give faint retinal greying following 1 minute of treatment. Beam diameters varied between 800 and 3000 µm.
The goal of TTT is to create and maintain tissue hyperthermia. It has been found that higher irradiance is needed for smaller laser spot diameters owing to the eYcient heat conductance of the choroidal circulation. Hence, laser irradiance must be inversely proportional to the spot diameter, which determines the size of the thermally aVected tissue volume. 28 For a 3 mm beam the settings were between 500-700 mW (irradiance 6-9 W/cm 2 ); for a 2 mm beam between 400-650 (irradiance 11-18 W/cm 2 ); and for a 1.2 mm beam 300-600 mW (irradiance 24-47 W/cm 2 ). A Volk (Mentor, OH, USA) area centralis contact lens was used in every case giving a magnification of 1.06× of the laser spot at the retina. Patients were anaesthetised with topical benoxinate 1%. Laser targeting was achieved with a diode red beam, the lesion being covered and extending 100 µm beyond the border. If whitening of the lesion was seen the laser power was reduced by 
Results

BASELINE CHARACTERISTICS:
The patient characteristics are summarised in Table 1 ; 44 eyes of 42 patients were treated. The mean patient age was 77.9 years (SD 8.38 years); 12 (27%) membranes were classic and 32 (73%) were occult with a mean area of 1.7 DA (range of 0.5-4.0 DA). Of the classic membranes one was extrafoveal, two were juxtafoveal, and nine were subfoveal. There was no correlation between visual acuity and size of CNV Z = −1.23 p=0.2. Haemorrhage was present in 7/12 of the classic membranes and 22/32 of the occult membranes. Seven patients were pseudophakic and two had glaucoma treated with timolol 0.25% BD. Table 1 shows the baseline data.
TREATMENT
The average number of treatments sessions was 1.80 (SD 0.87) spread over 1-6 months. PATIENT OUTCOME
Predominantly classic membranes
Predominantly classic membranes were closed in 9/12 (75%, CI: 62. (Table 3) . A Kaplan-Meyer estimate of a three line change in vision is shown in Figure 5 .
Discussion
The results from this study show that TTT is eVective in closing membranes in patients with CNV. Seventy seven per cent of membranes were closed at 6 months and only 7.1% developed recurrent CNV. This high closure rate was associated with a stabilisation or improvement in vision in 71% of patients with occult disease and 67% of patients with classic disease. These results compare well with the natural history of occult CNV where 63% of patients suVered 3 or more lines of visual loss in the first 6 months 28 and to the MPS study of classic membranes, where recurrence rates of 59% were reported. 10 Early clinical work recently published by Reichel et al have shown encouraging results for patients with occult subfoveal CNV. 27 They followed 16 eyes of 15 patients for 13 months following TTT for occult subfoveal CNV: 3/16 eyes experienced a 2+ line improvement, 9/16 stabilisation of vision (+/− 1 line) and 4/16 showed a significant decrease (>1 line). Optical coherence tomography and fluorescein angiography demonstrated resolution of the membranes. This compares with our findings that moderate loss of >2 lines occurred in 33% and severe loss >5 lines occurred in 0% of our patients with occult disease.
Results from this study compare well with the natural history of occult disease 29 and the recently reported results from the TAP study group, which evaluated photodynamic therapy (PDT) for predominantly classic membranes. 14 Their results show that, at 12 months, PDT stabilised vision in 61.2% (<3 lines lost) of the treatment group compared with 46% of the control group. The visual results of our study are comparable; 75% of patients, with predominantly classic membranes, having <3 lines of visual loss. However, TTT closed a higher proportion of CNV at 6 months (75%) compared with PDT (19%), and the control group (9%).
The MPS demonstrated that argon laser photocoagulation was eVective in closing classic membranes (72% at 6 months) but that this was associated with visual loss for subfoveal membranes. TTT may therefore combine the high rate of closure found with argon photocoagulation and the low recurrence rate with PDT, by closing CNV without damaging the neuroretina. Table 4 shows a comparison of the results between argon laser photocoagulation, photodynamic therapy, and transpupillary thermotherapy.
Transpupillary thermotherapy uses hyperthermia to disrupt the neovascular process and has been widely used for the treatment of small choroidal melanoma. 25 26 The laser is set to a low power with long pulse duration, the aim being to produce a moderate intralesional temperature rise (4-9°C), compared with 40°C for conventional laser photocoagulation. The lower temperature rise confines the thermal damage profile in the target tissue, thereby reducing damage to the middle and inner retina. Conventional photocoagulation may cause dense scotomata and recurrence following argon laser photocoagulation, particularly when treating subfoveal CNV. A large spot (0.8-3 mm) size, and a long low energy pulse enables complete treatment of the lesion and allows dose titration. The mechanism of action with TTT is still unclear. However, histological sections of treated human melanoma have demonstrated intravascular thrombosis, 30 31 which may account for the small amount of leakage, or haemorrhage following CNV treatment. Vascular closure may be precipitated by release of cytotoxic free radicals released from irradiated tissue. Certainly the relatively rapid involution of the CNV following TTT prevents further subretinal scarring and permanent photoreceptor damage, thereby limiting central scotomata in patients with subfoveal membranes.
The treatment variables have not been completely elucidated. In contrast with Reichel et al 27 we used several spots during one treatment session (average 4.25). It is clear that the end point is clinically diYcult to determine (as there is little retinal reaction) and that treatment parameters may need to be adjusted for the degree of neurosensory retinal detach- 32 However, low power settings used in TTT for CNV have meant that complications are rare and patient tolerance is good.
The precise role of TTT in the treatment of CNV needs to be further defined. However, the clinical improvement found in several of our patients and the high closure rate of occult CNV membranes, with little recurrence, suggest that this treatment will have a role in the management of some patient groups. Prospective, randomised controlled trials will further clarify the role of TTT in the treatment of CNV. SchaVer's sign had a 1% chance of having a retinal tear or hole and a 0.5% chance of having a lesion where prophylaxis was thought to be appropriate. Thus, SchaVer's sign has a negative predictive value of 99% in their series. They go on to recommend that if vitreous pigment is present then the patient should be referred for urgent vitreoretinal opinion while those with no pigment should be referred on a less urgent basis.
We would like to put these findings in perspective. The incidence of retinal breaks in patients aged 10 years or more who do not have any history of ocular disease is 6-14%. 2 Retinal breaks have been found in 37/250 (14.8%) of necropsy eyes with posterior vitreous detachment by Foos. 3 The incidence of retinal detachment is approximately 12/100 000 of the general population per year. 4 This suggests that less than 0.2% people with a retinal break eventually have a detachment of the retina. This value may be higher in patients with a symptomatic posterior vitreous detachment; however, it is reasonable to conclude that only a minority of retinal breaks will go on to cause a retinal detachment. Prophylactic treatment of retinal breaks by laser or cryotherapy is not without complications; also detachments can occur in eyes that have had prophylactic treatment. 5 Byer has reported that retinal breaks in unoperated eyes with posterior vitreous detachment that need treatment can be followed up without treatment, with only a minority progressing to retinal detachments. 6 We have a test that has a negative predictive value of 99%. We know that only a minority of patients who have a retinal tear or hole actually benefit from prophylactic treatment. Can we still justify referring all patients with a posterior vitreous detachment and no vitreous pigment for a specialist examination or even a follow up examination in the light of this knowledge?
The appropriate recommendation would be that all patients presenting with posterior vitreous detachment, no vitreous pigment, and no retinal tears or holes at initial examination can be safely discharged with an explanation of the warning symptoms which should prompt the patient to reattend.
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Reply EDITOR,-We thank Gupta and Prasad for their interest and comments on our recent paper. 1 We agree that the majority of retinal breaks probably do not progress to cause retinal detachment but suggest caution in the interpretation of data relating to asymptomatic rather than symptomatic tears, the latter having been shown to be associated with subsequent retinal detachment in approximately 30% of cases. 2 It is the management of recent onset, symptomatic posterior vitreous detachment (PVD) and associated retinal breaks which we addressed in our study. The rationale for treating fresh, symptomatic retinal breaks has been reviewed by numerous authors and is best summarised in the recent preferred practice pattern document produced by the American Academy of Ophthalmology. 3 The purpose of our study was to provide help to those practitioners seeing large numbers of patients with acute PVD, but who do not feel confident in the use of indentation ophthalmoscopy. The presence of vitreous pigment in patients presenting with acute PVD is indeed highly predictive of the presence of a retinal break, but a thorough retinal examination is still necessary.
In our series only one patient represented with a retinal break which had not been identified during initial indentation ophthalmoscopy. We agree that no routine follow up examination is required in most cases, provided a retinal break has been confidently excluded with indentation ophthalmoscopy and the PVD is judged to be complete, but that patients should be warned to reattend if further symptoms occur. Figure 4 (p 176). The axes are wrongly labelled. The y axis should read Post-TTa VA and the x axis should be Pre-TTT VA. We apologise for the error.
